Single and Multiple Ascending Doses of AZD1981 in Japan

NCT00698282 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 47

Last updated 2010-12-01

No results posted yet for this study

Summary

The purpose of this study is to study safety, tolerability and pharmacokinetics of AZD1981 in healthy Japanese subjects

Conditions

  • Healthy

Interventions

DRUG

AZD1981

Oral tablet, 250 mg single dose

DRUG

AZD1981

Suspension, 15, 75, 1000 and 2000 mg

DRUG

Placebo

Sponsors & Collaborators

Principal Investigators

  • Elizabeth Hancox · Europe Chiltern International Ltd, Berkshire, UK

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
20 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-08-31
Primary Completion
2008-10-31
Completion
2008-10-31

Countries

  • United Kingdom

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00698282 on ClinicalTrials.gov